Treatment of ranula wth intracystic injection of the streptococcal preparation OK-432.

Abstract

Intracystic injection of OK-432 was developed as a therapy for operatively difficult lymphangioma (cystic hygroma) and is currently becoming a treatment of first choice for this disease. We tried this therapy in 32 patients with ranula (oral floor type in 21 cases and plunging type in 11 cases). Disappearance or marked reduction of the lesion was observed in 31 patients (97%) who had this therapy, and local scarring did not occur in any patient. As side effects, local pain at the injection site and fever (37 degrees C to 39 degrees C) were observed in almost half of the patients who had this therapy, but such problems resolved within a few days. We treated the initial 4 cases in the hospital for 4 to 5 days, but after the safety of this method had been confirmed, we treated the other 28 cases on an outpatient basis. Thus, we confirmed that intracystic injection therapy with OK-432 is relatively safe and can be used as a substitute for surgery in the treatment of ranulas.

• Authors: Shigeru Fukase, Nobuo Ohta, Kazutoshi Inamura, Masaru Aoyagi
• Journal: The Annals of otology, rhinology, and laryngology (Ann Otol Rhinol Laryngol) Vol. 112 Issue 3 Pg. 214-20 (Mar 2003) ISSN: 0003-4894 [Print] United States
• PMID: 12656411 (Publication Type: Journal Article)

Chemical References

• Picibanil

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Female
• Humans
• Injections, Intralesional
• Male
• Middle Aged
• Picibanil (administration & dosage, therapeutic use)
• Ranula (drug therapy)